Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model.
Frederick W ThielenHedwig M BlommesteinLiesbeth E M OostenFriso G CalkoenArjan C LankesterJaap J ZwagingaKatarina Le BlancAlba RedondoFermin Sánchez-GuijoMattia AlgeriFranco LocatelliWim E FibbeCarin A Uyl-de GrootPublished in: European journal of haematology (2018)
The DM provides a comprehensive overview on the second-line treatment pathway for aGvHD and enables long-term predictions that can be used to perform a cost-effectiveness analysis comparing any treatment for SR-aGvHD.